Compugen shared its third-quarter 2026 results, showing about $3.8 million in sales and a loss of $5.8 million.

Nov 10, 2026, 2:05 AM ETResultsRead the original at prnewswire.com

Good for CGEN

Compugen reported $3.8 million in third-quarter revenue, up from $1.9 million, and said its $117.5 million cash reserve should fund operations into 2029. Completed trial enrollment and that runway outweigh the $5.8 million loss, though trial results are still pending.

CGEN · Compugen Ltd.

AI read · Good for CGEN

The AI's read

The cash gives Compugen time to keep working on its treatments through 2029. Finishing patient enrollment moves a key trial closer to results, but does not show whether the treatment works. The reported loss tempers the news, yet the cash runway and trial progress make the update favorable.

Get alerts for CGEN

Follow Compugen Ltd. (CGEN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CGEN

Free on the App Store and Google Play, or on the web.